In numerous neurological conditions such as Parkinson’s syndromes, stroke or traumatic brain injury, impaired sialorrhea may occur. IncobotulinumtoxinA is the first drug to be approved in Switzerland for the treatment of chronic sialorrhea in adults. The decisive factor was the SIAXI study – A Commentary.